Article Sidebar

Submitted
Feb 11, 2025
Published
Feb 11, 2025
Download
PDF
Statistic
Read Counter : 52 Download : 18

Main Article Content

Abstract

Autism spectrum disorders have distinct core symptoms, including struggles with social interactions and repetitive behaviours. These disorders involve complex neurodevelopmental problems, inflammation, and immune system dysfunction. Due to the underlying neurobiological causes of autism, researchers have explored the potential of cell-based therapies, such as stem cells, to treat the condition. Stem cells exhibit unique immunological properties, making them a promising area of study for autism treatment. This review examines autism's cellular and molecular abnormalities, potential stem cell therapies, animal models, and ongoing clinical trials. Research on autism's genetics shows that no proven cure exists, but studying stem cells has led to promising results, particularly with mesenchymal stem cells and human embryonic stem cells. These cells have been used to reduce autism severity and improve quality of life. Additionally, stem cells have been used to model various autism forms, such as Rett Syndrome and Fragile X Syndrome, allowing researchers to develop novel therapies. However, researchers must consider the ethical implications of their work, particularly when studying children, and prioritize their well-being and safety.

Keywords

Autism Spectrum Disorder Stem Cells Cell Therapy Modelling Treatment Hypoperfusion

Article Details

How to Cite
Shaik Parveen, Ravulapally Ashwitha, Thadakokkula Keerthana, Gutha Sisira Pushpa, & Rudroju Sri Vardhan Chary. (2025). Unlocking the potential of stem cell therapy for Autism: A new era in neurotherapeutics. International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(1), 102-110. Retrieved from https://ijrpp.com/ijrpp/article/view/623
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Iovene MR, Bombace F, Maresca R, et al. Intestinal dysbiosis and yeast isolation in stool of subjects with autism spectrum disorders. Mycopathologia. 2017;182(3–4):349–363.
  2. 2. Zeidan J, Fombonne E, Scorah J, et al. Global prevalence of autism: a systematic review update. Autism Res. 2022;15(5):778-790.
  3. 3. Elsabbagh M, Divan G, Koh YJ, et al. Global prevalence of autism and other pervasive developmental disorders. Autism Res. 2012;5(3):160–179.
  4. 4. Risi S et al. Combining information from multiple sources in the diagnosis of autism spectrum disorders. J. Am. Acad. Child Adolesc. Psychiatry 45, 1094–1103 (2006).
  5. 5. Rossignol DA, Bradstreet JJ, Van Dyke K, et al. Hyperbaric oxygen treatment in autism spectrum disorders. Med Gas Res. 2012;2(1):16.
  6. 6. S. Razavi, M. R. Razavi, H. Zarkesh Esfahani, M. Kazemi, and F. S. Mostafavi, “Comparing brain-derived neurotrophic factor and ciliary neurotrophic factor secretion of induced neurotrophic factor secreting cells from human adipose and bone marrow-derived stem cells,” Development, Growth & Differentiation, vol. 55, no. 6, pp. 648–655, 2013.
  7. 7. D. Drago, C. Cossetti, N. Iraci et al., “The stem cell secretome and its role in brain repair,” Biochimie, 2013.
  8. 8. D. Siniscalco, C. Giordano, U. Galderisi et al., “Long-lasting effects of human mesenchymal stem cell systemic administration on pain-like behaviors, cellular, and biomolecular modifications in neuropathic mice,” Frontiers in Integrative Neuroscience, vol. 5, article 79, 2011.
  9. 9. V. I. Zemel’ko, I. B. Kozhukharova, L. L. Alekseenko et al., “Neurogenic potential of human mesenchymal stem cells isolated from bone marrow, adipose tissue and endometrium: a comparative study,” Tsitologiia, vol. 55, no. 2, pp. 101–110, 2013.
  10. 10. S. A. Jackson, J. Schiesser, E. G. Stanley, and A. G. Elefanty, “Differentiating embryonic stem cells pass through ‘temporal windows’ that mark responsiveness to exogenous and paracrine mesendoderm inducing signals,” PLoS ONE, vol. 5, no. 5, Article ID e10706, 2010.
  11. 11. M. F. Pera, “Stem cells: the dark side of induced pluripotency,” Nature, vol. 471, no. 7336, pp. 46–47, 2011.
  12. 12. E. Galende, I. Karakikes, L. Edelmann et al., “Amniotic fluid cells are more efficiently reprogrammed to pluripotency than adult cells,” Cellular Reprogramming, vol. 12, no. 2, pp. 117–125, 2010.
  13. 13. P. V. Guillot, C. Gotherstrom, J. Chan, H. Kurata, and N. M. Fisk, “Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC,” Stem Cells, vol. 25, no. 3, pp. 646–654, 2007.
  14. 14. N. Sakuragawa, M. A. Elwan, S. Uchida, T. Fujii, and K. Kawashima, “Non-neuronal neurotransmitters and neurotrophic factors in amniotic epithelial cells: expression and function in humans and monkey,” Japanese Journal of Pharmacology, vol. 85, no. 1, pp. 20–23, 2001.
  15. 15. B. Short, N. Brouard, T. Occhiodoro-Scott, A. Ramakrishnan, and P. J. Simmons, “Mesenchymal stem cells,” Archives of Medical Research, vol. 34, no. 6, pp. 565–571, 2003.
  16. 16. M. Giuliani, M. Fleury, A. Vernochet et al., “Long-lasting inhibitory effects of fetal liver mesenchymal stem cells on Tlymphocyte proliferation,” PLoS ONE, vol. 6, no. 5, Article ID e19988, 2011.
  17. 17. D. Siniscalco, A. Sapone, C. Giordano et al., “Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders,” Journal of Autism and Developmental Disorders, 2013.
  18. 18. M. Locke, V. Feisst, and P. R. Dunbar, “Concise review: human adipose-derived stem cells: separating promise from clinical need,” Stem Cells, vol. 29, no. 3, pp. 404–411, 2011.
  19. 19. C. Zhou, B. Yang, Y. Tian et al., “Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes,” Cellular Immunology, vol. 272, no. 1, pp. 33–38, 2011.
  20. 20. Y.-C. Hsu, D.-C. Lee, and I.-M. Chiu, “Neural stem cells, neural progenitors, and neurotrophic factors,” Cell Transplantation, vol. 16, no. 2, pp. 133–150, 2007.
  21. 21. Caprnda M, Kubatka P, Gazdikova K, et al. Immunomodulatory effects of stem cells: therapeutic option for neurodegenerative disorders. Biomed Pharmacother. 2017;91:60–69.
  22. 22. Sharma A, Gokulchandran N, Sane H, et al. Autologous bone marrow mononuclear cell therapy for autism: an open label proof of concept study. Stem Cells Int. 2013;2013:623875.
  23. 23. Bjørklund G, Kern JK, Urbina MA, et al. Cerebral hypoperfusion in autism spectrum disorder. Acta Neurobiol Exp (Wars). 2018;78(1): 21–29.
  24. 24. Segal-Gavish H, Karvat G, Barak N, et al. Mesenchymal stem cell transplantation promotes neurogenesis and ameliorates autism related behaviors in BTBR mice. Autism Res. 2016;9(1):17–32.
  25. 25. Ha S, Park H, Mahmood U, Ra JC, Suh YH, Chang KA. Human adipose-derived stem cells ameliorate repetitive behavior, social deficit and anxiety in a VPA-induced autism mouse model. Behav Brain Res. 2017;317:479–484.
  26. 26. Siniscalco D, Bradstreet JJ, Sych N, et al. Mesenchymal stem cells in treating autism: Novel insights. World J Stem Cells. 2014; 6: 173-178.
  27. 27. Sun JM, Kurtzberg J. Stem cell therapies in cerebral palsy and autism spectrum disorder. Dev Med Child Neurol. 2021; 63: 503-510.
  28. 28. Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient’s bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol 2007; 211: 27-35
  29. 29. Z, Weiss K, Isaac J, Lange C, Westenfelder C: Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005, 289:F31-42.
  30. 30. Kadri T, Lataillade JJ, Doucet C, Marie A, Ernou I, Bourin P, JoubertCaron R, Caron M, Lutomski D: Proteomic study of Galectin-1 expression in human mesenchymal stem cells. Stem Cells Dev 2005, 14:204-212.
  31. 31. Hallett PJ, Deleidi M, Astradsson A, et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson’s disease. Cell Stem Cell. 2015;16(3):269–274.
  32. 32. Liu X, Campanac E, Cheung HH, et al. Idiopathic autism: cellular and molecular phenotypes in pluripotent stem cell-derived neurons. Mol Neurobiol. 2017;54(6):4507–4523.
  33. 33. aussion G, Rocha C, Bernard G, et al. Patient-Derived Stem Cells, Another in vitro Model, or the Missing Link Toward Novel Therapies for Autism Spectrum Disorders?. Front Pediatr. 2019; 7: 225.
  34. 34. Brito A, Russo FB, Muotri AR, et al. Autism spectrum disorders and disease modeling using stem cells. Cell Tissue Res. 2018; 371: 153-160.
  35. 35. Reilly J, Gallagher L, Chen JL, et al. Bio-collections in autism research. Mol Autism. 2017; 8: 34.
  36. 36. Russo FB, Freitas BC, Pignatari GC, et al. Modeling the Interplay Between Neurons and Astrocytes in Autism Using Human Induced Pluripotent Stem Cells. Biol Psychiatry. 2018; 83: 569-578.
  37. 37. Tse HF, Yiu KH, Lau CP: Bone marrow stem cell therapy for myocardial angiogenesis. Curr Vasc Pharmacol 2007, 5:103-112.
  38. 38. Ohab JJ, Fleming S, Blesch A, Carmichael ST: A neurovascular niche for neurogenesis after stroke. J Neurosci 2006, 26:13007-13016.
  39. 39. Riordan NH, Chan K, Marleau AM, Ichim TE: Cord blood in regenerative medicine: do we need immune suppression? J Transl Med 2007, 5:8.
  40. 40. Hassall O, Bedu-Addo G, Adarkwa M, Danso K, Bates I: Umbilicalcord blood for transfusion in children with severe anaemia in under-resourced countries. Lancet 2003, 361:678-679.